| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA649:Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
|
Medicine details |
|
| Medicine name | polatuzumab vedotin (Polivy) |
| Formulation | powder for concentrate for solution for infusion |
| Reference number | 3684 |
| Indication | In combination with bendamustine and rituximab for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/12/2019 |
| NICE guidance | |
| Commercial arrangement | PAS |